EPRX Eupraxia Pharmaceuticals Inc.

6.138USD8.780 CAD · TSX-0.90%Mkt Cap: 412.87M USDP/E: —

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug de…

Institutional holders13 on file

Key Statistics

Company
Market Cap412.87M USD
Enterprise Value351.28M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-38.58M USD
Revenue/Share—
Last Price6.138 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees49
CountryCA
SectorHealthcare
IndustryBiotechnology
ISINCA29842P1053
Valuation
P/E (Trailing)—
P/E (Forward)-5.96
PEG—
EV/EBITDA-7.60
EV/Revenue—
P/S—
P/B4.59
EPS (TTM)-1.49 USD
EPS (Forward)-1.47 USD
52W Range
5.13825% of range9.143
52W High9.143 USD
52W Low5.138 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-47.02%
ROA-44.78%
ROIC—
ROCE-47.73%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-28.55M USD
CapEx (TTM)588.95K USD
FCF Margin—
FCF Yield-5.68%
Net Debt-123.00M USD
Net Debt/EBITDA1.86
Net Debt/FCF—
Balance Sheet
Debt/Equity0.00
Current Ratio12.25
Quick Ratio11.94
Book Value/Sh1.91 USD
Cash/Share1.88 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)12.34 USD
Upside (mean)+101.0%
Target Range12.09 USD – 12.58 USD
12.09+101.0% to mean12.58
# Analysts2
Ownership
Shares Out.67.27M
Float56.82M
Insiders11.71%
Institutions50.29%
Short Interest
Short Ratio4.7d
Short % Float0.82%
Short % Out.0.66%
Shares Short445.11K
Short (prev mo.)154.89K
Technical
SMA 507.450 (-17.6%)
SMA 2007.023 (-12.6%)
Beta1.33
S&P 52W Chg12.00%
Avg Vol (30d)95.09K
Avg Vol (10d)108.45K
Technical Indicators
RSI (14)39.4
MACD-0.1720
MACD Signal-0.0478
MACD Hist.-0.1242
BB Upper8.117 USD
BB Middle6.979 USD
BB Lower5.840 USD
BB Width32.62%
ATR (14)0.5322 USD
Vol Ratio (20d)0.78x

About Eupraxia Pharmaceuticals (TSE: EPRX)

›

Eupraxia Pharmaceuticals (TSE: EPRX) is listed on the Toronto Stock Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 49 employees.

The shares were at 8.780 CAD on 19 November 2026, up 10.3% over 52 weeks. Its 52-week range is 7.350 CAD to 13.08 CAD: the price is 32.9% below the high and 19.5% above the low.

Its market capitalisation is 590.62M CAD.

Eupraxia Pharmaceuticals reports return on equity of -47.0% and an operating margin of 0.0%.

It holds more cash than debt, a net cash position of 123.00M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 2 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 17.65 CAD is 101.0% above the current price. The next earnings report is expected on 16 March 2027.